Brokerages Expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to Announce -$0.27 Earnings Per Share

Wall Street analysts forecast that NeuBase Therapeutics, Inc. (NASDAQ:NBSE) will report ($0.27) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for NeuBase Therapeutics’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.26). NeuBase Therapeutics posted earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year over year growth rate of 35%. The business is scheduled to announce its next quarterly earnings results on Wednesday, December 22nd.

According to Zacks, analysts expect that NeuBase Therapeutics will report full-year earnings of ($0.95) per share for the current financial year, with EPS estimates ranging from ($0.99) to ($0.88). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover NeuBase Therapeutics.

NeuBase Therapeutics (NASDAQ:NBSE) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05).

Several brokerages have issued reports on NBSE. Zacks Investment Research raised shares of NeuBase Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 29th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of NeuBase Therapeutics in a report on Monday, September 13th.

Shares of NASDAQ NBSE opened at $3.89 on Monday. NeuBase Therapeutics has a 12-month low of $3.26 and a 12-month high of $12.89. The company has a market capitalization of $127.27 million, a PE ratio of -4.27 and a beta of -0.01. The firm’s 50-day moving average is $3.72 and its two-hundred day moving average is $4.67.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in NeuBase Therapeutics by 5.4% during the first quarter. JPMorgan Chase & Co. now owns 51,222 shares of the company’s stock worth $379,000 after purchasing an additional 2,641 shares during the last quarter. Heritage Wealth Advisors increased its position in shares of NeuBase Therapeutics by 80.0% in the second quarter. Heritage Wealth Advisors now owns 9,000 shares of the company’s stock worth $63,000 after acquiring an additional 4,000 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of NeuBase Therapeutics by 5.2% in the second quarter. Goldman Sachs Group Inc. now owns 109,685 shares of the company’s stock worth $525,000 after acquiring an additional 5,450 shares in the last quarter. Royal Bank of Canada increased its position in shares of NeuBase Therapeutics by 121.1% in the first quarter. Royal Bank of Canada now owns 11,244 shares of the company’s stock worth $83,000 after acquiring an additional 6,158 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in NeuBase Therapeutics during the 2nd quarter valued at $33,000. 31.85% of the stock is currently owned by institutional investors and hedge funds.

NeuBase Therapeutics Company Profile

NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.

Recommended Story: How is the S&P 500 index different from the DJIA?

Get a free copy of the Zacks research report on NeuBase Therapeutics (NBSE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.